Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satraplatin in Metastatic Breast Cancer
NCT00265655Phase 2Completed
- Sponsor
- Agennix AG
- Start
- Nov 2005
- Primary completion
- Jan 2008
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of satraplatin in breast cancer, sponsored by Agennix AG. Primary endpoint: Objective Response Rate at 1 year. Started Nov 2005; status: completed.
02
Drugs
satraplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00265655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00265655.